Vyome Therapeutics, Inc. (“Vyome”), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that...
Effective as of Commencement of Trading on August 15, 2025
Heavily shareholder-aligned board and management team completely replaces ReShape team as Vyome prepares for public listing on August 15, 2025 ...
Expected to be Effective as of Commencement of Trading on August 15, 2025
Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved Stockholders are encouraged to vote FOR...
IRVINE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will...
Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys Shareholders are encouraged to vote FOR Proposals 1, 2,...